A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People with Early Psychosis

Schizophrenia Bulletin

Volumn 41, Issue 2, 2015, Pages 483-493

  Cacciotti Saija, Cristina ^a   Langdon, Robyn ^b   Ward, Philip B ^c   Hickie, Ian B ^a   Scott, Elizabeth M ^a   Naismith, Sharon L ^a   Moore, Loretta ^a   Alvares, Gail A ^a   Redoblado Hodge, Marie Antoinette ^d   Guastella, Adam J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

emotion recognition; neuropeptides; schizophrenia; social behavior

Indexed keywords

NOSE SPRAY; OXYTOCIN;

ADOLESCENT; ADULT; ARTICLE; ATTRIBUTIONAL BIAS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCHIZOPHRENIA; SELF REPORT; SOCIAL COGNITION; SOCIAL COGNITION TRAINING; SOCIAL INTERACTION; SOCIAL INTERACTION TEST; THEORY OF MIND; YOUNG ADULT; COGNITIVE THERAPY; MULTIMODALITY CANCER THERAPY; PERCEPTION; PROCEDURES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NASAL SPRAYS; OXYTOCIN; PSYCHOTIC DISORDERS; SOCIAL PERCEPTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940825450     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu094     Document Type: Article

References (60)

1. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr Bull. 2009;35:493-508.
2. Insel TR. Rethinking schizophrenia. Nature. 2010;468:187-193.
3. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884-897.
4. Pantelis C, Yücel M, Bora E, et al. Neurobiological markers of illness onset in psychosis and schizophrenia: the search for a moving target. Neuropsychol Rev. 2009;19:385-398.
5. Hickie IB, Scott J, Hermens DF, et al. Clinical classification in mental health at the cross-roads: which direction next? BMC Med. 2013;11:125.
6. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
7. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
8. Green MF, Bearden CE, Cannon TD, et al. Social cognition in schizophrenia, Part 1: performance across phase of illness. Schizophr Bull. 2012;38:854-864.
9. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12:524-538.
10. Guastella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm Behav. 2012;61:410-418.
11. Goldman MB, Gomes AM, Carter CS, Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl). 2011;216:101-110.
12. Averbeck BB, Bobin T, Evans S, Shergill SS. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med. 2012;42:259-266.
13. Davis MC, Lee J, Horan WP, et al. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013;147:393-397.
14. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132:50-53.
15. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010;68:678-680.
16. Modabbernia A, Rezaei F, Salehi B, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs. 2013;27:57-65.
17. Kéri S, Kiss I, Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci. 2009;4:287-293.
18. Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res. 2010;124:13-21.
19. Caldwell HK, Stephens SL, Young WS III. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry. 2009;14:190-196.
20. Popik P, Vetulani J, van Ree JM. Low doses of oxytocin facilitate social recognition in rats. Psychopharmacology (Berl). 1992;106:71-74.
21. Penn DL, Roberts DL, Combs D, Sterne A. Best practices: the development of the Social Cognition and Interaction Training program for schizophrenia spectrum disorders. Psychiatr Serv. 2007;58:449-451.
22. Roberts DL, Penn DL. Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res. 2009;166:141-147.
23. Roberts DL, Penn DL, Labate D, Margolis SA, Sterne A. Transportability and feasibility of social cognition and interaction training (SCIT) in community settings. Behav Cogn Psychother. 2010;38:35-47.
24. Roberts DL, Combs DR, Willoughby M, et al. A randomized, controlled trial of social cognition and interaction training (SCIT) for outpatients with schizophrenia spectrum disorders [published online ahead of print January 13, 2014]. Br J Clin Psychol. doi: 10.1111/bjc.12044.
25. Bartholomeusz CF, Allott K, Killackey E, Liu P, Wood SJ, Thompson A. Social cognition training as an intervention for improving functional outcome in first-episode psychosis: a feasibility study. Early Interv Psychiatry. 2013;7:421-426.
26. Horan WP, Kern RS, Green MF, Penn DL. Social cognition training for individuals with schizophrenia: emerging evidence. Am J Psychiatr Rehabil 2008;11:205-252.
27. Davis MC, Green MF, Lee J, et al. Oxytocin-augmented social cognitive skills training in schizophrenia [published online ahead of print March 18, 2014]. Neuropsychopharmacol. doi: 10.1038/npp.2014.68.
28. Scott EM, Hermens DF, Glozier N, Naismith SL, Guastella AJ, Hickie IB. Targeted primary care-based mental health services for young Australians. Med J Aust. 2012;196:136-140.
29. Marsh P, Langdon R, McGuire J, Harris A, Polito V, Coltheart M. An open clinical trial assessing a novel training program for social cognitive impairment in schizophrenia. Australas Psychiatry. 2013;21:122-126.
30. Marsh PJ, McGuire J, Polito V, et al. SoCog: Manual for Mental-state Reasoning and Emotion Recognition Training in Schizophrenia. Sydney, Australia: Macquarie University; 2013.
31. Russell TA, Chu E, Phillips ML. A pilot study to investigate the effectiveness of emotion recognition remediation in schizophrenia using the micro-expression training tool. Br J Clin Psychol. 2006;45:579-583.
32. Guastella AJ, Hickie IB, McGuinness MM, et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology. 2013;38:612-625.
33. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0), Biometrics Research. New York: New York State Psychiatric Institute; 1995.
34. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI) Manual. San Antonio, TX: Psychological Corporation; 1999.
35. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87:733-742.
36. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001;42:241-251.
37. Andreasen NC. Scale for the assessment of positive symptoms. Iowa City: University of Iowa; 1984.
38. Andreasen NC. Scale for the assessment of negative symptoms. Iowa City: University of Iowa; 1983.
39. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157:853-859.
40. Guastella AJ, Hermens DF, Van Zwieten A, et al. Social cognitive performance as a marker of positive psychotic symptoms in young people seeking help for mental health problems. Schizophr Res. 2013;149:77-82.
41. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67:692-694.
42. Young A, Perrett D, Calder A, Sprengelmeyer R, Ekman P. Facial Expressions of Emotion: Stimuli and Tests (FEEST). Edmunds, UK: Thames Valley Test Company; 2002.
43. Adolphs R, Tranel D. Amygdala damage impairs emotion recognition from scenes only when they contain facial expressions. Neuropsychologia. 2003;41:1281-1289.
44. Langdon R, Michie PT, Ward PB, McConaghy N, Catts SV, Coltheart M. Defective self and/or other mentalising in schizophrenia: a cognitive neuropsychological approach. Cogn Neuropsychiatry 1997;2:167-193.
45. Stone VE, Baron-Cohen S, Knight RT. Frontal lobe contributions to theory of mind. J Cogn Neurosci. 1998;10:640-656.
46. Baron-Cohen S, Wheelwright S. The empathy quotient: an investigation of adults with Asperger syndrome or high functioning autism, and normal sex differences. J Autism Dev Disord. 2004;34:163-175.
47. Combs DR, Penn DL, Wicher M, Waldheter E. The Ambiguous Intentions Hostility Questionnaire (AIHQ): a new measure for evaluating hostile social-cognitive biases in paranoia. Cogn Neuropsychiatry. 2007;12:128-143.
48. Randolph C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, TX: The Psychological Corporation; 1998.
49. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995;33:335-343.
50. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32:959-976.
51. Heimberg RG, Mueller GP, Holt CS, Hope DA, Liebowitz MR. Assessment of anxiety in social interaction and being observed by others: the Social Interaction Anxiety Scale and the Social Phobia Scale. Behavior Therapy 1993;23:53-73.
52. Guy W. Clinical global impression scale. ECDEU Assessment Manual for Psychopharmacology, Revised. 1976;338:218-222.
53. Patterson TL, Moscona S, McKibbin CL, Davidson K, Jeste DV. Social skills performance assessment among older patients with schizophrenia. Schizophr Res. 2001;48:351-360.
54. Buhrmester D, Furman W, Wittenberg MT, Reis HT. Five domains of interpersonal competence in peer relationships. J Pers Soc Psychol. 1988;55:991-1008.
55. Sheehan D. The Anxiety Disease. New York, NY: Charles Scribner & Sons; 1983.
56. Faul F, Erdfelder E, Lang AG, Buchner A. G.∗Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-191.
57. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Earlbaum associates; 1988.
58. Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independentgroups designs. Psychol Methods. 2002;7:105-125.
59. Goldman M, Marlow-O'Connor M, Torres I, Carter CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res. 2008;98:247-255.
60. Szeszko PR, Narr KL, Phillips OR, et al. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr Bull. 2012;38:569-578.